Varda Raises $250 Million at $1.6 Billion on Government Payload Demand

Varda Space Industries raised a $250 million Series D at a $1.6 billion valuation, led by Lux Capital and Natural Capital, the company announced Sept. 30. The round takes the El Segundo, California, orbital-manufacturing startup to $598 million raised since 2021.

Yahoo Finance reports the round as closed at $250 million, while Tech Funding News lists it at $251 million. Neither says whether the $1.6 billion is a pre-money or post-money figure, which matters: if it is post-money, the new cash is 15.6 percent of the company, and if it is pre-money, closer to 13.5 percent.

What the $1.6 billion is set against

Varda has about 275 employees, according to Yahoo Finance's account, which puts the valuation near $5.8 million per head. About 18 percent of those staff have pharmaceutical backgrounds, a figure that sits oddly beside the customer mix: 70 percent of next year's payload customers are government, and only the remainder is commercial pharmaceutical work.

Co-founder Will Bruey said he expects the ratio to flip by 2032. He also named the milestone that would justify it: "The biggest milestone in the company's history is going to be right around the turn of the decade when we take one of those microgravity-enabled formulations and we inject it into a human in the clinic."

That is a clinical-trial event roughly four years out, and a valuation set today rests on government payloads paying the bills until then.

The round table does not reach $598 million

Tech Funding News itemises the company's history. The rounds it lists add up to $579 million, which leaves $19 million of the reported $598 million total unexplained by equity rounds.

Round	Date	Amount
Seed	December 2020	$9 million
Series A	July 2021	$42 million
Series B	April 2024	$90 million
Series C	July 2025	$187 million
Series D	September 2026	$251 million

Neither source says what the $19 million is. It could be debt, a grant or a contract advance, and that is a guess; the sources do not say. The Series D is also 34 percent larger than the Series C, which closed 14 months earlier.

Six missions, and two different launch counts

Varda has flown six missions on its W-Series capsule since 2023, and five of them re-entered successfully, according to Yahoo Finance. The company has booked 28 launches with several providers for 2027 to 2029, Yahoo Finance reports. Tech Funding News gives a different framing: more than a dozen further launches and re-entries through 2028.

Both can be true, since one counts booked slots and the other counts planned missions, but the two sources do not reconcile them, and the 28 figure is the only one that mentions a provider split.

The next two flights, W-8 and W-9, were set to fly on SpaceX's Transporter-18, per Tech Funding News. W-8 carries sensors and thermal protection materials for a U.S. military study. W-9 carries a Department of Defense payload for hypersonic flight navigation testing. Neither is a drug.

Who else is in orbit

Yahoo Finance names two competitors: SpaceX's Starfall program and the startup Inversion Space, which it lists as rivals in orbital manufacturing and hypersonic research. Varda's pharmaceutical work includes a May 2026 collaboration with United Therapeutics to study microgravity formulations for rare pulmonary disease treatments, per Tech Funding News.

Shahin Farshchi, a partner at Lux Capital, is quoted by Tech Funding News calling Varda "the first and only company delivering a real cadence of launches and re-entries." Other orbital hardware is also looking for flight slots, as Google's Suncatcher test of four TPUs shows. For another round announced without a valuation basis, see Supabase's $150 million from GIC.

The next checkable event is the Transporter-18 manifest. If W-8 and W-9 reach orbit and return, Varda will have flown eight missions, and the government share of its book will have been demonstrated in hardware rather than in a percentage.